These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 20811179)

  • 1. FDA approves new treatment for late-onset Pompe disease.
    Home Healthc Nurse; 2010 Sep; 28(8):457. PubMed ID: 20811179
    [No Abstract]   [Full Text] [Related]  

  • 2. First treatment for Pompe disease.
    FDA Consum; 2006; 40(4):3. PubMed ID: 17245826
    [No Abstract]   [Full Text] [Related]  

  • 3. The importance of nutritional status in the prognosis of late onset Pompe disease.
    Papadimas GK; Terzis G; Papadopoulos C; Spengos K; Manta P
    Mol Genet Metab; 2010 Aug; 100(4):389. PubMed ID: 20488740
    [No Abstract]   [Full Text] [Related]  

  • 4. Prognostic factors for late-onset Pompe disease with enzyme replacement therapy: The two sides of low BMI.
    Ravaglia S; Carlucci A; Danesino C
    Mol Genet Metab; 2010 Aug; 100(4):388. PubMed ID: 20472481
    [No Abstract]   [Full Text] [Related]  

  • 5. 24-months results in two adults with Pompe disease on enzyme replacement therapy.
    Vielhaber S; Brejova A; Debska-Vielhaber G; Kaufmann J; Feistner H; Schoenfeld MA; Awiszus F
    Clin Neurol Neurosurg; 2011 Jun; 113(5):350-7. PubMed ID: 21477922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA balks at Myozyme scale-up.
    Mack G
    Nat Biotechnol; 2008 Jun; 26(6):592. PubMed ID: 18536660
    [No Abstract]   [Full Text] [Related]  

  • 7. Pompe disease in infants and children.
    Kishnani PS; Howell RR
    J Pediatr; 2004 May; 144(5 Suppl):S35-43. PubMed ID: 15126982
    [No Abstract]   [Full Text] [Related]  

  • 8. Pompe disease therapy presents coverage challenge.
    Morrow T
    Manag Care; 2006 Jun; 15(6):63-4. PubMed ID: 16838889
    [No Abstract]   [Full Text] [Related]  

  • 9. Enzyme replacement in Pompe disease with an alpha-glucosidase-low density lipoprotein complex.
    Williams JC; Murray AK
    Birth Defects Orig Artic Ser; 1980; 16(1):415-23. PubMed ID: 7004520
    [No Abstract]   [Full Text] [Related]  

  • 10. Pompe disease (glycogen storage disease type II) in Argentineans: clinical manifestations and identification of 9 novel mutations.
    Palmer RE; Amartino HM; Niizawa G; Blanco M; Pomponio RJ; Chamoles NA
    Neuromuscul Disord; 2007 Jan; 17(1):16-22. PubMed ID: 17056254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pregnancy during enzyme replacement therapy for late-onset acid maltase deficiency.
    Zagnoli F; Leblanc A; Blanchard C
    Neuromuscul Disord; 2013 Feb; 23(2):180-1. PubMed ID: 23290485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic criteria for late-onset (childhood and adult) Pompe disease.
    American Association of Neuromuscular & Electrodiagnostic Medicine
    Muscle Nerve; 2009 Jul; 40(1):149-60. PubMed ID: 19533647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Avalglucosidase alfa: First Approval.
    Dhillon S
    Drugs; 2021 Oct; 81(15):1803-1809. PubMed ID: 34591286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infantile-onset Pompe disease: a diagnosis not to miss.
    Dixon CA; Anderson JB; Ruddy RM; Cripe LH
    Pediatr Emerg Care; 2010 Apr; 26(4):293-5. PubMed ID: 20386415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alglucosidase alfa: new drug. Pompe disease: a short-term benefit.
    Prescrire Int; 2007 Dec; 16(92):240-1. PubMed ID: 18092404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pompe disease: a review of the current diagnosis and treatment recommendations in the era of enzyme replacement therapy.
    Katzin LW; Amato AA
    J Clin Neuromuscul Dis; 2008 Jun; 9(4):421-31. PubMed ID: 18525427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme replacement therapy in adult-onset glycogenosis II: is quantitative muscle MRI helpful?
    Pichiecchio A; Poloni GU; Ravaglia S; Ponzio M; Germani G; Maranzana D; Costa A; Repetto A; Tavazzi E; Danesino C; Moglia A; Bastianello S
    Muscle Nerve; 2009 Jul; 40(1):122-5. PubMed ID: 19533640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pompe's disease. Part II. Treatment strategies and enzyme replacement].
    Illés Z; Várdi Visy K
    Ideggyogy Sz; 2009 Sep; 62(9-10):299-307. PubMed ID: 19835271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Late-onset Pompe disease: the lessons drawn from the use of Myosime
    Laforêt P
    Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():18-21. PubMed ID: 30943155
    [No Abstract]   [Full Text] [Related]  

  • 20. A randomized study of alglucosidase alfa in late-onset Pompe's disease.
    van der Ploeg AT; Clemens PR; Corzo D; Escolar DM; Florence J; Groeneveld GJ; Herson S; Kishnani PS; Laforet P; Lake SL; Lange DJ; Leshner RT; Mayhew JE; Morgan C; Nozaki K; Park DJ; Pestronk A; Rosenbloom B; Skrinar A; van Capelle CI; van der Beek NA; Wasserstein M; Zivkovic SA
    N Engl J Med; 2010 Apr; 362(15):1396-406. PubMed ID: 20393176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.